>Reviewing and Understanding Clinical Papers
- Venue: DSRU, Bursledon Hall, Southampton
- Date: 20 Sep - 21 Sep 2017
Cost per delegate:
- Or £166.66 + VAT academic
(NHS, academic units, public sector organisations, registered charities, students)
- Or £233.34 + VAT standard
- Or £166.66 + VAT academic
Book your place
Sorry, This course is not currently available to book. Please check back soon or check our Course Calendar.
Clinical papers present strong arguments for research evidence. It is important to examine papers in a systematic and objective way in terms of quality, validity, and relevance of results in specific situations. The Reviewing and Understanding Clinical Papers course provides an overview of the process of objective review of medical and scientific literature. Senior professionals from a variety of backgrounds and organisations will be on hand to facilitate the learning process. As well as incorporating theoretical elements, the programme includes interactive sessions enabling delegates to draw their own evidence based conclusions.
This course is aimed at:
• Pharmaceutical industry personnel from areas including pharmacovigilance, clinical research, medical affairs, medical writing, regulatory affairs, medical information, post-marketing product support and safety
• Candidates about to sit postgraduate exams with assessment of critical appraisal skills as a component eg. in pharmaceutical medicine
• Staff from regulatory authorities
• General practice or public health personnel
• NHS, NHS R&D and other research organisations and agency staff including researchers, doctors, nurses, medical information pharmacists, pharmaceutical advisors or other professions allied to medicine
Please click here to download the programme.
Please note that the course dates and programme may be subject to change.
This course is endorsed by UKCPA and recognised by PharmaTrain.
“Speakers very professional with a lot of experience and a very systematic approach.” Reviewing and Understanding a Clinical Paper Delegate 2016
“Excellent content presented in a relaxed informal style.” Reviewing and Understanding a Clinical Paper Delegate 2016
“Fantastic support and education from facilitators in workshops.” Reviewing and Understanding a Clinical Paper Delegate 2016
“Excellent introduction with clear speakers. The workshops were excellent for interacting and clarifying unclear issues.” Reviewing and Understanding a Clinical Paper Delegate 2015
“Excellent overview of critical appraisal.” Reviewing and Understanding a Clinical Paper Delegate 2015
- To provide delegates with an introduction to the principles of evidenced-based medicine (EBM) with emphasis on various types of clinical questions and tools available to answer them
- To review key pharmacoepidemiological study designs and basic statistical concepts
- To provide delegates with basic knowledge and the skills needed to formulate research questions and hypotheses, develop research protocols, critically evaluate and analyse scientific and medical journals, and to conduct computerised searches and literature reviews
- Awareness of key study design and basic statistical concepts
- Understanding of the critical appraisal process
- Practical experience in applying critical appraisal
- Gain additional skills in drawing conclusions on research findings
- An appreciation of the rationale behind EBM
On successful completion of this course delegates should be able to:
- Integrate key data for critical appraisal in individual personal practice
- Assemble appropriate instruments and resources for use in critical appraisal, and apply these tools to appraise published research and judge reliability
- Formulate and manage effective individual personal information searching skills
Our next course
Pharmacovigilance Planning and Risk Management
A pro-active approach to risk management of drug safety is vital throughout the whole life-cycle of a medicinal product. The aim of this course is to critically explore existing and developing strategies to plan and optimise risk management activities for known and potential risks of a newly approved product.